AwadAGVorugantiLNPHeslegraveRJ. The aim of antipsychotic medications: What are they and are they being achieved?CNS Drugs1995:4:8–16.
2.
AwadAG. Antipsychotic medications in schizophrenia: How satisfied are our patients? In: Clear perspectives—management issues in schizophrenia: Patient satisfaction, compliance and outcomes in schizophrenia. London (UK): Shire Hall Ltd; 1999. p 1–6.
3.
AwadAG. Antipsychotic medications: Compliance and attitudes towards treatment. Curr Opin Psychiatry. Forthcoming.
4.
AwadAGVorugantiLNP. Quality of life and new antipsychotics in schizophrenia: Are patients better off?Int J Soc Psychiatry1999;45:268–75.
5.
VorugantiLNPSlomkaPZabelPCostaGSoAMatterAAwadAG. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: The correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology2001;25:642–50.
6.
VorugantiLNPAwadAG. Neuroleptic dysphoria as a variant of extrapyramidal side-effects of antipsychotic medications. Can J Psychiatry2004;49:285–9.
7.
de HaanLLavalayeJLinszenDDingemansPMAJBooijJ.Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry2000;157:1019–20.
8.
de HaanLLavalayeJvan BruggenMVan NimwegenLBooijJAmelsvoortT, and others. Subjective experiences and dopamine D2 receptor occupancy in patients treated with antipsychotics: Clinical implications. Can J Psychiatry2004;49:290–6.
9.
ChambersAKrystalJSelfD.A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry2001;50:71–83.
10.
VorugantiLNPCorteseLOwyeumiLKottedaVChernovskyZZirulS, and others. Switching from conventional to novel antipsychotic drugs: Results of a prospective naturalistic study. Schizophr Res2002;57:201–8.
11.
AwadAGVorugantiLNP. New antipsychotics, compliance, quality of life and subjective tolerability: Are patients better off?Can J Psychiatry2004;49:297–302.
